Kaken Pharmaceutical : Reference Data of Financial Statements for the 1Q of Fiscal 2022

Consolidated Financial Result for 1st Quarter of Fiscal 2022

(Reference Data of Consolidate Financial Statement

for 1st Quarter of Fiscal 2022)

August 3, 2022

KAKEN PHARMACEUTICAL CO., LTD.

Corporate Communications

Tel: [phone]

Fax: [phone]

Email: [e-mail]

1. Consolidated Financial Results for 1st Quarter of Fiscal 2022
				(amounts are rounded down to the nearest million Yen)
	FY2021	FY2021	FY2022	Change		Plan	Change
	1Q	1Q	Amount	%	FY2022	Amount	%
Net sales	18,453	76,034	18,197	(255)	98.6%	76,400	366	100.5%
Operating profit	4,421	17,064	4,056	(365)	91.7%	15,000	(2,064)	87.9%
Ratio of net sales	24.0%	22.4%	22.3%			19.6%
Ordinary profit	4,660	17,542	4,332	(328)	93.0%	15,500	(2,042)	88.4%
Ratio of net sales	25.3%	23.1%	23.8%			20.3%
Profit	3,362	9,549	2,907	(455)	86.5%	12,000	2,451	125.7%
Ratio of net sales	18.2%	12.6%	16.0%			15.7%
Comprehensive income	3,297	9,563	3,014	(283)	91.4%
R&D Expense	1,865	8,420	2,030	164	108.8%	10,400	1,980	123.5%

2. Sales of Main Pharmaceuticals and Medical Devices (non-consolidated)

(amounts are rounded down to the nearest million Yen)

	FY2021	FY2021	FY2022	Change	Plan	Change
	1Q	1Q	(%)	FY2022	(%)
Onychomycosis treatment	4,970	18,449	4,813	96.8%	18,100	98.1%
Clenafin
Anti-osteoarthritis agent	4,888	18,853	4,448	91.0%	17,500	92.8%
Artz
Post-operativeanti-adhesive	2,118	8,433	2,006	94.7%	8,900	105.5%
Seprafilm
Wound-healing agent	697	2,769	706	101.4%	2,800	101.1%
Fiblast Spray
Anti-dysuria	495	1,936	479	96.8%	2,000	103.3%
Ebrantil
Primary axillary hyperhydrosis	294	950	413	140.4%	2,000	210.5%
Ecclock Gel
Periodontal regenerative agent	213	860	226	105.8%	1,000	116.3%
Regroth
Lumber disc herniation treatment	103	381	104	101.0%	400	105.0%
Hernicore
Total generic products	2,178	8,831	2,108	96.8%	9,500	107.6%

• KAKEN PHARMACEUTICAL CO., LTD.

3. New Drug Development Pipeline

Development	Target	Development	Remarks
Code	Indication	Stage
KMW-1	Removal of eschar with	Filed	In-licensed from MediWound Ltd.
thermal burns	Overseas brand name: NexoBrid
KAR	Head lice infestation	P III	In-licensed from Arbor Pharmaceuticals, LLC.
Overseas brand name: Sklice
ART-001	Refractory vascular	P II	Developed by ARTham Therapeutics Inc.
malformations
ART-648	Bullous pemphigoid	P II	Developed by ARTham Therapeutics Inc.
BBI-4000	Primary palmoplantar	P I	Additional indication of Ecclock primary
hyperhydrosis	axillary hyperhydrosis treatment
KP-483	Solid tumors	P I	Products from in-house drug discovery
(immuno-oncology)
NM26-2198	Atopic dermatitis	P I	Phase I clinical studies in preparation
Co-development with Numab Therapeutics AG

• KAKEN PHARMACEUTICAL CO., LTD.